Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy

Autor: Mandrioli, J, Biguzzi, S, Guidi, C, Sette, E, Terlizzi, E, Ravasio, A, Casmiro, M, Salvi, F, Liguori, R, Rizzi, R, Pietrini, V, Borghi, A, Rinaldi, R, Fini, N, Chierici, E, Santangelo, M, Granieri, E, Mussuto, V, De Pasqua, S, Georgoulopoulou, E, Fasano, A, Errals, Group, Ferro, S, D'Alessandro, R
Přispěvatelé: Mandrioli, J., Biguzzi, S., Guidi, C., Sette, E., Terlizzi, E., Ravasio, A., Casmiro, M., Salvi, F., Liguori, R., Rizzi, R., Pietrini, V., Borghi, A., Rinaldi, R., Fini, N., Chierici, E., Santangelo, M., Granieri, E., Mussuto, V., de Pasqua, S., Georgoulopoulou, E., Fasano, A., Errals, Group, Ferro, S., D'Alessandro, R.
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Popis: Very few studies examined trend over time of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and factors influencing it; previous studies, then, included only patients attending tertiary ALS Centres. We studied ALSFRS-R decline, factors influencing this trend and survival in a population-based setting. From 2009 onwards, a prospective registry records all incident ALS cases among residents in Emilia Romagna (population: 4.4 million). For each patient, demographic and clinical details (including ALSFRS-R) are collected by caring physicians at each follow-up. Analysis was performed on 402 incident cases (1279 ALSFRS-R assessments). The average decline of the ALSFRS-R was 0.60 points/month during the first year after diagnosis and 0.34 points/month in the second year. ALSFRS-R decline was heterogeneous among subgroups. Repeated measures mixed model showed that ALSFRS-R score decline was influenced by age at onset (p < 0.01), phenotype (p = 0.01), body mass index (BMI) (p < 0.01), progression rate at diagnosis (ΔFS) (p < 0.01), El Escorial Criteria-Revised (p < 0.01), and FVC% at diagnosis (p < 0.01). Among these factors, at multivariate analysis, only age, site of onset and ΔFS independently influenced survival. In this first population-based study on ALSFRS-R trend, we confirm that ALSFRS-R decline is not homogeneous among ALS patients and during the disease. Factors influencing ALSFRS-R decline may not match with those affecting survival. These disease modifiers should be taken into consideration for trials design and in clinical practice during discussions with patients on prognosis.
Databáze: OpenAIRE